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XDiscussion
Dr Joren Madsen (Boston, Mass). I congratulate the speaker
and the Society for recognizing the importance of this work.
Enthusiasm in xenotransplantation has waxed and waned over
the last 20 years. Dr Shumway used to say, half jokingly but half
seriously, that xenotransplantation was the future of heart
transplantation and always would be. However, these compelling
new findings suggest that the future of xenotransplantation may
be closer than we all thought. Indeed, achieving a greater than
500-day survival of a pig heart in a discordant baboon recipient
sets a new standard for the field and allows us to begin thinking
about human application again.
My major concern in reading your article was your use of the
heterotopic heart transplant model in which the heart graft is not
life sustaining and graft survival times can be easily overestimated.
However, your use of the innovative telemetry techniques to
continuously monitor intracardiac pressures has temperedThe Journal of Thoracic and Carthose concerns. I have 3 questions that relate to your recipients in
group D.
What was the specific immune or nonimmune mechanism that
led to the loss of 2 of the 5 recipients in group D? Will additional
immunotherapeutics or genetic modifications be required to
achieve 100% survival?
Dr Mohiuddin. The 2 animals that rejected in group D were
explanted. One of them had long-term fever with no cause to be
found, and because of strict animal care rules, we had to euthanize
this animal. This animal showed no significant necropsy finding
but had some inclusion CMV bodies in its testes. There was no
evidence of any active CMV disease in this animal. The other
animal that we explanted had repeated episodes of ventricular
fibrillation, and we took the heart out to satisfy our Animal Care
and Use Committee concerns.
In both these hearts, we did see a lot of fibrosis and myocyte
damage on histology, but there were areas preserved that had
normal myocardium. It is hard to pinpoint the exact cause of rejec-
tion, and all these animals had high levels of antibodies against
non-GAL antigens. It is possible that both the antibody and the
TM played significant roles in the delayed rejection of these hearts.
Additional expression of human genes to avert TM and careful
adjustment of anti-CD40 dose may yield an even better survival.
Dr Madsen. Many investigators believe that successful xeno-
transplantation will require the induction of immune tolerance.
Do you believe or have any evidence that your protocol resulted
in immune tolerance, and if so, would you consider weaning all
drugs at a certain time point to limit the morbidity and mortality
related to chronic immunosuppression?
Dr Mohiuddin. In one of the animals, which has survived for
approximately 600 days now, we have done some preliminary
studies. We have done mixed lymphocyte reaction assays from
the lymphocytes and saved cells from the donor pig, and we
have seen that this animal was hyporesponsive to the donor-spe-
cific antigen. But when we tested responses against cells from a
third-party pig, these cells were responsive. So there is an element
of ‘‘tolerance’’ in there, but we need to do a lot more studies to
evaluate that. We have already started to taper the immunosuppres-
sive drugs in 2 of 3 surviving animals. In explanted grafts, we have
found no evidence of chronic vasculopathy.
Dr Madsen. The last question concerns infections. Other have
found that reactivation of pig and even baboon CMV seems to have
serious adverse effects in pig-to-baboon xenotransplantation.
Given your exclusive use of SPF animals, are you concerned that
the same excellent results may not be achieved in non-SPF animals
or, for that matter, in humans?
Dr Mohiuddin. We tested the levels of the non-Gal antibodies
in SPF baboons, and they were found to be comparable to levels
found in humans. As far as the antibody levels, we are satisfied
with what we have, but I fully acknowledge your concern for
CMV. Although we have not seen active CMV disease in any of
our animals, the literature shows that this is a big concern, and
we will have to keep a close eye on that.
Dr Madsen. Thank you and congratulations.
Dr R. Duane Davis (Durham, NC). This is an interesting series
of experiments. Let me follow up a little bit on what Joren was
asking in terms of the antibody-mediated rejection assessment
on the organs that are still working. Have you been followingdiovascular Surgery c Volume 148, Number 3 1113
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Xthe anti-swine antibody titers? You mentioned you started with
low-titer baboons as recipients. How low were they? What has
happened over the period of time in terms of the development of
anti-pig, non-GAL antibodies?
Dr Mohiuddin. As I mentioned earlier, the non-Gal antibody
levels in SPF baboons are lower than in the conventional baboons
and comparable to the levels in humans. The levels vary from ba-
boon to baboon. We give 4 doses of rituximab that completely
takes care of B cells, and these B cells do not return until day
60. After that period, we do see somewhat higher titers of anti-
bodies than their baseline levels. In the earlier groups, we did
find antibody deposition in the heart, but what role they are playing
is not evident.
DrDavis.When you say by using that dose you are clearing
all of the B cells, are you looking at the B1 cells in the peri-
toneal cavity, and along those lines are you looking at the cen-
tral compartment? Obviously, you have plasma cells and some
of the other long lines that antiCD20 does not actually
address.
DrMohiuddin. Exactly, that is our concern also, because CD20
does not take care of plasma cells, people have shown the role of
bortezomib in eliminating plasma cells, which we have not tried. A
single dose of rituximab can eliminate the peripheral circulating B
cells. But what we have shown earlier, and Chris McGregor’s
group, is that you need at least 4 doses to completely wipe out B
cells in all compartments.
Dr Y. Joseph Woo (Philadelphia, Pa). Do the standard xeno-
transplantation models entail continuous heparin anticoagulation?1114 The Journal of Thoracic and Cardiovascular SurDr Mohiuddin. Yes, and we have seen a beneficial effect of it.
We keep these animals on tether and continuous heparin infusion.
Dr Woo. Among the prior models that yielded survival only up
to 500 days, did these involve anticoagulation? How much is the
anticoagulation benefiting your model?
DrMohiuddin.Wemonitor their ACTand try to keep the level
twice the level of the baseline number, and we maintain it
throughout. Others have tried various forms of anticoagulation
for variable periods of time; some of them have tried for a few
months and others for only a few weeks. We are the only ones, I
think, who have used it on a continuous basis.
Dr Woo. So it may be contributing significantly?
Dr Mohiuddin. Definitely.
Dr Woo. In this heterotopic model, can the grafts undergo an
endovascular endomyocardial biopsy?
Dr Mohuddin. Yes, the histology results I showed in my pre-
sentation are the 1-year biopsy results from our long-term graft.
Dr Woo. They weren’t the final pathology?
DrMohiuddin. The long-term graft results were biopsy results,
but for the other groups, we have explanted the heart, and the re-
sults shown are from the final pathology.
DrWoo. Did you ever modify the anti-rejection regimen on the
basis of biopsy findings?
Dr Mohiuddin. Not really, because the major problem is the
antibodies in xenotransplantation. Our main goal is to first tackle
the antibody and the molecules that are incompatible with this
model. We do initiate rescue therapy with steroids when we see
onset of rejection, but this therapy has not helped us so far.gery c September 2014
